COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu
Trial record 1 of 1 for:    BP-007
Previous Study | Return to List | Next Study

ProSpace™ Balloon System Pivotal Study BP-007

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03400150
Recruitment Status : Recruiting
First Posted : January 17, 2018
Last Update Posted : January 14, 2021
Information provided by (Responsible Party):

Brief Summary:
The ProSpace™ System is intended to temporarily position the anterior rectal wall away from the prostate during radiotherapy for prostate cancer and in creating this space it is the intent of the ProSpace System to reduce the radiation dose delivered to the anterior rectum. ProSpace is a balloon composed of a biodegradable material that maintains that space for the entire course of prostate radiotherapy treatment and is completely absorbed by the patient's body over time.

Condition or disease Intervention/treatment Phase
Prostate Cancer Device: ProSpace Other: Control Not Applicable

Detailed Description:
This study will be a prospective, multi-center, randomized, double-arm, single blind, concurrently controlled study to assess the safety and efficacy of the ProSpace Balloon in prostate cancer subjects undergoing radiotherapy by means of intensity modulation radiation therapy (IMRT).

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 222 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Subjects will be randomized in a 2:1 ratio (ProSpace implantation:control)
Masking: Single (Participant)
Masking Description: Study subjects are blinded to group assignment.
Primary Purpose: Supportive Care
Official Title: CLINICAL PROTOCOL for the INVESTIGATION Of the ProSpace™ Balloon System Pivotal Study BP-007
Actual Study Start Date : January 3, 2018
Estimated Primary Completion Date : March 30, 2021
Estimated Study Completion Date : May 31, 2021

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Prostate Cancer

Arm Intervention/treatment
Experimental: ProSpace group
Marking + ProSpace implantation + IMRT
Device: ProSpace
ProSpace balloon implantation

Sham Comparator: Control group
Marking + IMRT
Other: Control
Control - Marking & IMRT are standard of care for prostate cancer - there is no study-specific intervention

Primary Outcome Measures :
  1. Adverse Event Rate of Occurrence [ Time Frame: Duration of at least 2 days through 6 months ]
    Rate of occurrence of Grade 1 or greater rectal adverse events and implantation procedure related adverse events through 6 months.

  2. Reduction in Rectal Radiation Exposure [ Time Frame: 6 months ]
    Reduction of at least 25% of the volume of the rectum receiving greater or equal to 70 Gy (VRectum70) when compared to pre-implantation values.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Be at least 18 years of age
  • Have been histologically diagnosed with invasive adenocarcinoma of the prostate, at clinical stage T1-T3 (as determined by a biopsy taken within 9 months of the screening visit)
  • Be scheduled for radiation therapy (XRT) by means of IMRT

Exclusion Criteria:

  • Any prior invasive malignancy (except non-melanomatous skin cancer) unless the subject has been disease free for a minimum of 5 years
  • Prior radical prostatectomy
  • Prior cryosurgery or radiotherapy for prostate cancer, or other local therapy for prostate cancer
  • Prior radiotherapy to the pelvis, including brachytherapy
  • History of prior surgery involving the rectum or anus
  • Prior surgical procedure involving the peri-rectal and/or peri-prostatic area

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03400150

Layout table for location contacts
Contact: Joyce Dunsmore 703-628-8603

Layout table for location information
United States, California
Western Radiation Oncology Recruiting
Apple Valley, California, United States, 95008
Contact: Jennifer Woltz    650-485-9904   
KSK Medical Center Recruiting
Irvine, California, United States, 92618
Contact: Kenneth Tokita, MD    949-417-1100   
United States, Florida
Advanced Urology Institute Recruiting
Daytona Beach, Florida, United States, 32114
Contact: Jonelle Morsley    386-239-8535   
United States, Illinois
Rush University Cancer Center Recruiting
Chicago, Illinois, United States, 60612
Contact: Estefania Gonzalez Arreaza   
United States, Maryland
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center Recruiting
Baltimore, Maryland, United States, 21287
Contact: Hamza Hasan    410-955-8652   
Chesapeake Urology Research Associates Recruiting
Owings Mills, Maryland, United States, 21117
Contact: Richard Hudes, MD    443-231-1203   
United States, Nevada
Urology Nevada Recruiting
Reno, Nevada, United States, 89521
Contact: Michael Kos, MD    775-850-6505   
United States, New York
Advanced Radiation Center of New York Recruiting
Lake Success, New York, United States, 11042
Contact: Jessica Blanco    516-394-9600   
New York University Langone Health Recruiting
New York, New York, United States, 10016
Contact: Ashley Brown   
United States, South Carolina
Medical University of South Carolina (MUSC) Recruiting
Charleston, South Carolina, United States, 29425
Contact: Alan Brisendine    843-792-9007   
Assuta Ashdod Recruiting
Ashdod, Israel
Contact: Yewgeniya Vitkin    972-72-3398279   
Rabin Medical Center Recruiting
Petah Tikva, Israel
Contact: Yarra Barr   
Maastro Recruiting
Maastricht, Netherlands
Contact: Evelin van der Peet    31884455874   
Institute of Maria Skłodowska-Oncology Centre Recruiting
Warsaw, Poland
Contact: Pitor Saniewski   
CUF Porto Instituto Recruiting
Porto, Portugal
Contact: Paulo Costa    +351-22 00 34 001   
United Kingdom
Beatson West of Scotland Cancer Centre Recruiting
Glasgow, United Kingdom
Contact: Elaine MacLeod   
Sponsors and Collaborators
Additional Information:
Layout table for additonal information
Responsible Party: BioProtect Identifier: NCT03400150    
Other Study ID Numbers: BP-007
First Posted: January 17, 2018    Key Record Dates
Last Update Posted: January 14, 2021
Last Verified: July 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Device Product Not Approved or Cleared by U.S. FDA: Yes
Additional relevant MeSH terms:
Layout table for MeSH terms
Prostatic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Prostatic Diseases